Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Publishing your trial protocols with Acta Oncologica; your contribution to scientific transparency

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. European cancer rehabilitation and survivorship, 2018: one of a kind

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Exercise-mediated improvement of depression in patients with gastro-esophageal junction cancer is linked to kynurenine metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Advanced Electrocardiogram Analysis in the Amitriptyline-poisoned Pig Treated with Activated Charcoal Haemoperfusion

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: To compare 18F-sodium fluoride positron emission tomography/computed tomography (NaF PET/CT) and 99mTc-labelled diphosphonate bone scan (BS) for the monitoring of bone metastases in patients with prostate cancer undergoing anti-cancer treatment.

MATERIAL AND METHODS: Data from 64 patients with prostate cancer were included. The patients received androgen-deprivation therapy (ADT), next-generation hormonal therapy (NGH) or chemotherapy. The patients had a baseline scan and 1-3 subsequent scans during six months of treatment. Images were evaluated by experienced nuclear medicine physicians and classified for progressive disease (PD) or non-PD according to the Prostate Cancer Working Group 2 (PCWG-2) criteria. The patients were also classified as having PD/non-PD according to the clinical and prostate-specific antigen (PSA) responses.

RESULTS: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD during treatment (McNemar's test, p = .18). The agreement between BS and NaF PET/CT for PD/non-PD was moderate (Cohen's kappa 0.53, 95% confidence interval 0.26-0.79). Crude agreement between BS and NaF PET/CT for the assessment of PD/non-PD was 86% (89% for ADT, n = 28; 88% for NGH, n = 16, and 80% for chemotherapy, n = 20). In most discordant cases, BS found PD when NaF PET/CT did not, or BS detected PD on an earlier scan than NaF PET/CT. Biochemical progression (27%) occurred more frequently than progression on functional imaging (BS, 22% and NaF PET/CT, 14%). Clinical progression was rare (11%), and almost exclusively seen in patients receiving chemotherapy.

CONCLUSION: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD; however, BS seemingly detects PD by the PCWG-2 criteria earlier than NaF-PET, which might be explained by the fact that NaF-PET is more sensitive at the baseline scan.

Original languageEnglish
JournalActa oncologica (Stockholm, Sweden)
Volume57
Issue number8
Pages (from-to)1063-1069
Number of pages7
ISSN0284-186X
DOIs
Publication statusPublished - Aug 2018

    Research areas

  • Aged, Aged, 80 and over, Bone Neoplasms/diagnostic imaging, Fluorine Radioisotopes, Humans, Male, Middle Aged, Positron Emission Tomography Computed Tomography/methods, Prospective Studies, Prostatic Neoplasms/drug therapy, Radionuclide Imaging/methods, Radiopharmaceuticals, Sodium Fluoride, Treatment Outcome

ID: 56147502